Photodynamic therapy photofrin

Misawa, J., Moriwaki, S.I., Kohno, E., Hirano, T., Tokura, Y., Takigawa, M. (2005) The role of low-density lipoprotein receptors in sensitivity to killing by Photofrin-mediated photodynamic therapy in cultured human tumor cell lines. J. Dermatol. Sci. July 20. 

Flahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, Smith D, Glatstein E, Fraker DL, Busch TM (2006) Photofrin uptake in the tumor and normal tissues of patients receiving intra-peritoneal photodynamic therapy. Clin Cancer Res 12 5464-5470. 

Li Lb, Luo Re, Liao Wj, Zhang Mj, Luo Yl, Miao Jx (2006) Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma. Photodiagnosis and Photodynamic Therapy 3 266-271. 

Work during the last ten years on photodynamic therapy (PDT) has established the methodology as effective in the early treatment of cancers, and in the treattnent of certain skin disorders and viral infections. Approval by the regulatory authorities for sensitisers in this process began in 1993 when Canada allowed the use of Photofrin (QLT Therapeutics), an action followed later by most countries around the world. Now many other companies have sensitisers at late stage clinical dials (2001), see below in Table 4.5. An excellent introduction to the chemistry of this topic is provided in the book written by Bonnett. ... 

Igarashi A et al (2003) Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer. Toxicol Lett 145 133-141... 

Amphiphilic porphyrins, e.g., hematoporphyrins (photofrin) or chlorin (aspartyl amide) derivatives, are used in photodynamic therapy of tumors using red laser light. They tend to accumulate in tumor cells when injected intravenously, can be regioselectively irradiated via thin optical fibers, and then produce toxic singlet oxygen upon irradiation. Most useful are porphyrins with... 

S.L. Gibson, K.R. van der Meid, R.S. Murant, R. Hilf (1990). Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of Photofrin II. Br. J. Cancer, 61, 553-557. 

I.P. van Geel, H. Oppelaar, J.P. Marijnissen, F.A. Stewart (1996). Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat. Res., 145, 602-609. 

X.Y. He, R.A. Sikes, S. Thomsen, L.W. Chung, S.L. Jacques (1994). Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines. Photochem. PhotobioL, 59, 468-473. 

K. Adams, A.J. Rainbow, B.C. Wilson, G. Singh (1999). In vivo resistance to photofrin-mediated photodynamic therapy in radiation-induced fibrosarcoma cells resistant to in vitro Photofrin-mediated photodynamic therapy. J. Photochem. Photobiol. B, 49, 136-141. 

W.J. de Vree, M.C. Essers, J.F. Koster, W. Sluiter (1997). Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res., 57, 2555-2558. 

W.-S. Chan, N. Brasseur, C. La Madeleine, J.E. van Lier (1996). Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin tumor cell survival and blood flow. Anticancer Res., 16, 1887-1892. 

M.O. Dereski, L. Madigan, M. Chopp (1994). Brain response to photodynamic therapy with Photofrin, monsulfonated aluminum phthalocyanine and tin purpurin. In D.A. Cortese (Ed.), PROC SPIE 2371, 579-581. 

Z.P. Bernstein, B.D. Wilson, A.R. Oseroff, C.M. Jones, S.E. Dozier, J.S. Brooks, R. Cheney, L. Foulke, T.S. Mang, D.A. Bellnier, T.J. Dougherty (1999). Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi s sarcoma. AIDS, 13, 1697-704. 

F. Jiang, L. Lilge, B. Logie, Y. Li, M. Chopp (1997). Photodynamic therapy of 9L gliosarcoma with liposome-delivered Photofrin. Photochem. Photobiol., 65(4), 701-706. 

Koren treated two patients suffering from recurrence or residual cancer of the vulva after conventional therapy [86]. Photodynamic therapy using Photofrin systemically resulted in partial response with recurrence 2-3 months following PDT and complete response (CR) lasting >12 months. 

---